Bild/Picture ®Thomas Ferber/Oncoletter

  • Oral Abstract Session - Immunotherapy
  • Poster Discussion Session - Immunotherapy
  • Oral Abstract Session - Molecularly Targeted Agents and Tumor Biology Primary
  • Poster Discussion Session - Molecularly Targeted Agents and Tumor Biology Primary

Oral Abstract Session - Immunotherapy

Abstract 2500: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.

Presenter: Ulka N. Vaishampayan, MD | University of Michigan Cancer Center

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2500

----------------------------------------------------------------------------------------------------------------------------

Abstract 2501: First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.

Presenter: Aung Naing

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2501

----------------------------------------------------------------------------------------------------------------------------

Abstract 2502: Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.

Presenter: Elena Garralda

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2502

----------------------------------------------------------------------------------------------------------------------------

Abstract: 2503: Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors.

Presenter: Melissa Lynne Johnson

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2503

----------------------------------------------------------------------------------------------------------------------------

Abstract 2504: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).

Presenter: Gerald Steven Falchook

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2504

----------------------------------------------------------------------------------------------------------------------------

Abstract 2505: Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results.

Presenter: Martin Gutierrez

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2505

----------------------------------------------------------------------------------------------------------------------------

Abstract 2506: A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors.

Presenter: Sanjay Goel

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2506

----------------------------------------------------------------------------------------------------------------------------

Abstract 2507: Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.

Presenter: Steven Michael Blum

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2507

----------------------------------------------------------------------------------------------------------------------------

Abstract 2508: Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada.

Presenter: Abdul Rafeh Naqash

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2508

----------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Oral Abstract Session you need an ASCO Annual Meeting registration

----------------------------------------------------------------------------------------------------------------------------

POSTER SESSION

Immunotherapy

https://meetings.asco.org/2022-asco-annual-meeting/14355?presentation=210135#210135

 

Poster Discussion Session - Immunotherapy

Abstract 2512: Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors.

Presenter: Ye Guo | Poster: 168

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2512

------------------------------------------------------------------------------------------------------------------------

Abstract 2513: A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Presenter: Philippe L. Bedard, | Poster: 169

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2513

------------------------------------------------------------------------------------------------------------------------

Abstract 2514: Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study.

Presenter: Aung Naing | Poster: 170

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2514

------------------------------------------------------------------------------------------------------------------------

Abstract 2515: First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI).

Presenter: Marwan Fakih | Poster: 171

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2515

------------------------------------------------------------------------------------------------------------------------

Abstract 2516: Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.

Presenter: Vinod P. Balachandran | Poster: 172

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2516

------------------------------------------------------------------------------------------------------------------------

Abstract 2517: Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.

Presenter: Siqing Fu | Poster: 173

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2517

------------------------------------------------------------------------------------------------------------------------

Abstract: 2518: Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies.

Presenter: Julius Strauss | Poster: 174

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2518

------------------------------------------------------------------------------------------------------------------------

Abstract 2519: Identifying mechanisms of acquired immune escape from sequential, paired biopsies.

Presenter: F. Stephen Hodi | Poster: 175

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2519

------------------------------------------------------------------------------------------------------------------------

Abstract 2520: Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].

Presenter: Jacob Stephen Thomas | Poster: 176

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2520

------------------------------------------------------------------------------------------------------------------------

Abstract 2521: First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.

Presenter: Eugene R Ahn | Poster: 177

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2521

------------------------------------------------------------------------------------------------------------------------

Abstract 2522: The association of pre-existing autoimmune disease and immune-related adverse events secondary to immune checkpoint inhibition therapy in a UK multicenter cohort.

Presenter: Anna Claire Olsson-Brown | Poster: 178

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2522

------------------------------------------------------------------------------------------------------------------------

Abstract 2523: Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.

Presenter: Arthur Daban | Poster: 179

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2523

------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session you need an ASCO Annual Meeting registration

Oral Abstract Session - Molecularly Targeted Agents and Tumor Biology Primary

Abstract 3000: A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors.

Presenter: Lingying Wu

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3500

----------------------------------------------------------------------------------------------------------------------------

Abstract 3001: Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).

Presenter: Rahul Raj Aggarwal

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3501

----------------------------------------------------------------------------------------------------------------------------

Abstract 3002: Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).

Presenter: Erika P. Hamilton

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3502

----------------------------------------------------------------------------------------------------------------------------

Abstract 3003: First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Presenter: Ecaterina Elena Dumbrava

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3503

----------------------------------------------------------------------------------------------------------------------------

Abstract 3004: A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS).

Presenter: Mrinal M. Gounder

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3504

----------------------------------------------------------------------------------------------------------------------------

Abstract 3005: A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors.

Presenter: Mark Yarchoan

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3505

----------------------------------------------------------------------------------------------------------------------------

Abstract 3006: CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.

Presenter: Daniel R. Carrizosa,

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3506

----------------------------------------------------------------------------------------------------------------------------

Abstract 3007: Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.

Presenter: Yohann Loriot

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3507

----------------------------------------------------------------------------------------------------------------------------

Abstract 3008: Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.

Presenter: Funda Meric-Bernstam

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3508

----------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Oral Abstract Session you need an ASCO Annual Meeting registration

----------------------------------------------------------------------------------------------------------------------------

POSTER SESSION

Molecularly Targeted Agents and Tumor Biology Primary

https://meetings.asco.org/2022-asco-annual-meeting/14358?presentation=210903#210903

 

Poster Discussion Session - Molecularly Targeted Agents and Tumor Biology Primary

Abstract 3009: Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

Presenter: Kieuhoa Tran Vo | Poster: 1

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3009

------------------------------------------------------------------------------------------------------------------------

Abstract 3010: Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.

Presenter: Anne S. Tsao | Poster: 2

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3010

------------------------------------------------------------------------------------------------------------------------

Abstract 3011: A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.

Presenter: Xiaojie Hu | Poster: 3

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3011

------------------------------------------------------------------------------------------------------------------------

Abstract 3012: NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.

Presenter: Liza C Villaruz | Poster: 4

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3012

------------------------------------------------------------------------------------------------------------------------

Abstract 3013: First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.

Presenter: Sarina Anne Piha-Paul | Poster: 5

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3013

------------------------------------------------------------------------------------------------------------------------

Abstract 3014: Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors.

Presenter: T.R. Jeffry Evans | Poster: 6

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3014

------------------------------------------------------------------------------------------------------------------------

Abstract 3015: Expanding clinical actionability in individual patient profiles with the Molecular Oncology Almanac.

Presenter: Brendan Michael Reardon | Poster: 7

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3015

------------------------------------------------------------------------------------------------------------------------

Abstract 3016: Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM).

Presenter: Arnaud Bayle | Poster: 8

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3016

------------------------------------------------------------------------------------------------------------------------

Abstract 3017: Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers.

Presenter: Matthew Mackay  | Poster: 9

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3017

------------------------------------------------------------------------------------------------------------------------

Abstract 3018: Differential diagnosis of hematologic and solid tumors using targeted transcriptome and artificial intelligence.

Presenter: Hong Zhang | Poster: 10

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3018

------------------------------------------------------------------------------------------------------------------------

Abstract 3019: AI-enabled identification prediction of homologous recombination deficiency (HRD) from histopathology images.

Presenter: Gowhar Shafi | Poster: 11

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3019

------------------------------------------------------------------------------------------------------------------------

Abstract 3020: A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity.

Presenter: Dmitry Zarubin | Poster: 12

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3020

------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session you need an ASCO Annual Meeting registration

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close